These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31960060)

  • 1. Safety of high-dose ivermectin: a systematic review and meta-analysis.
    Navarro M; Camprubí D; Requena-Méndez A; Buonfrate D; Giorli G; Kamgno J; Gardon J; Boussinesq M; Muñoz J; Krolewiecki A
    J Antimicrob Chemother; 2020 Apr; 75(4):827-834. PubMed ID: 31960060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadening the range of use cases for ivermectin - a review of the evidence.
    Kositz C; Bradley J; Hutchins H; Last A; D'Alessandro U; Marks M
    Trans R Soc Trop Med Hyg; 2022 Mar; 116(3):201-212. PubMed ID: 34323283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial.
    Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008106. PubMed ID: 32176703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?
    Jittamala P; Monteiro W; Smit MR; Pedrique B; Specht S; Chaccour CJ; Dard C; Del Giudice P; Khieu V; Maruani A; Failoc-Rojas VE; Sáez-de-Ocariz M; Soriano-Arandes A; Piquero-Casals J; Faisant A; Brenier-Pinchart MP; Wimmersberger D; Coulibaly JT; Keiser J; Boralevi F; Sokana O; Marks M; Engelman D; Romani L; Steer AC; von Seidlein L; White NJ; Harriss E; Stepniewska K; Humphreys GS; Kennon K; Guerin PJ; Kobylinski KC
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009144. PubMed ID: 33730099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers.
    Muñoz J; Ballester MR; Antonijoan RM; Gich I; Rodríguez M; Colli E; Gold S; Krolewiecki AJ
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006020. PubMed ID: 29346388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ivermectin mass drug administration for malaria vector control on ectoparasites and soil-transmitted helminths: a cluster randomized trial.
    Kositz C; Drammeh M; Vasileva H; Houghton J; Ashall J; D'Alessandro U; Marks M; Bradley J
    Int J Infect Dis; 2022 Dec; 125():258-264. PubMed ID: 36336245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis.
    Abegunde AT; Ahuja RM; Okafor NJ
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011146. PubMed ID: 26771164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study.
    Levy M; Martin L; Bursztejn AC; Chiaverini C; Miquel J; Mahé E; Maruani A; Boralevi F;
    Br J Dermatol; 2020 Apr; 182(4):1003-1006. PubMed ID: 31344258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study).
    Lake SJ; Phelan SL; Engelman D; Sokana O; Nasi T; Boara D; Gorae C; Schuster T; Grobler AC; Osti MH; Andrews R; Marks M; Whitfeld MJ; Romani L; Kaldor J; Steer A
    BMJ Open; 2020 Aug; 10(8):e037305. PubMed ID: 32868360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya.
    Smit MR; Ochomo E; Aljayyoussi G; Kwambai T; Abong'o B; Bayoh N; Gimnig J; Samuels A; Desai M; Phillips-Howard PA; Kariuki S; Wang D; Ward S; Ter Kuile FO
    JMIR Res Protoc; 2016 Nov; 5(4):e213. PubMed ID: 27856406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis?
    Chandler RE
    Am J Trop Med Hyg; 2018 Feb; 98(2):382-388. PubMed ID: 29210346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Systemic adverse reactions with ivermectin treatment of scabies].
    Sparsa A; Bonnetblanc JM; Peyrot I; Loustaud-Ratti V; Vidal E; Bédane C
    Ann Dermatol Venereol; 2006 Oct; 133(10):784-7. PubMed ID: 17072195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly.
    Kamgno J; Gardon J; Gardon-Wendel N; Demanga-Ngangue ; Duke BO; Boussinesq M
    Trans R Soc Trop Med Hyg; 2004 Aug; 98(8):496-504. PubMed ID: 15186939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru.
    Failoc-Rojas VE; Silva-Díaz H; Maguiña JL; Rodriguez-Morales AJ; Díaz-Velez C; Apolaya-Segura M; Valladares-Garrido MJ
    Parasite Epidemiol Control; 2023 Nov; 23():e00320. PubMed ID: 37731824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial.
    Buonfrate D; Salas-Coronas J; Muñoz J; Maruri BT; Rodari P; Castelli F; Zammarchi L; Bianchi L; Gobbi F; Cabezas-Fernández T; Requena-Mendez A; Godbole G; Silva R; Romero M; Chiodini PL; Bisoffi Z
    Lancet Infect Dis; 2019 Nov; 19(11):1181-1190. PubMed ID: 31558376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Human Scabies with Oral Ivermectin. Eczematous Eruptions as a New Non-Reported Adverse Event.
    Sanz-Navarro J; Feal C; Dauden E
    Actas Dermosifiliogr; 2017 Sep; 108(7):643-649. PubMed ID: 28385424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis.
    Makunde WH; Kamugisha LM; Massaga JJ; Makunde RW; Savael ZX; Akida J; Salum FM; Taylor MJ
    Filaria J; 2003 Nov; 2(1):15. PubMed ID: 14613509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse reactions to the ivermectin treatment of onchocerciasis patients: does infection with the human immunodeficiency virus play a role?
    Kipp W; Bamhuhiiga J; Rubaale T; Kabagambe G
    Ann Trop Med Parasitol; 2005 Jun; 99(4):395-402. PubMed ID: 15949187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial.
    Foy BD; Alout H; Seaman JA; Rao S; Magalhaes T; Wade M; Parikh S; Soma DD; Sagna AB; Fournet F; Slater HC; Bougma R; Drabo F; Diabaté A; Coulidiaty AGV; Rouamba N; Dabiré RK
    Lancet; 2019 Apr; 393(10180):1517-1526. PubMed ID: 30878222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.